SK29599A3 - Benzamidine derivatives substituted by cyclic amino acid or cyclic hydroxy acid derivatives and their use as anti-coagulants - Google Patents

Benzamidine derivatives substituted by cyclic amino acid or cyclic hydroxy acid derivatives and their use as anti-coagulants Download PDF

Info

Publication number: SK29599A3
Authority: SK; Slovakia
Prior art keywords: oxy; hydroxy; methyl; alkyl; phenoxy
Prior art date: 1996-09-12

Application number

SK295-99A

Other languages

English (en)

Slovak (sk)

Inventor

Monica Kochanny

Michael M Morrissey

Howard P Ng

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-09-12

Filing date

1997-09-11

Publication date

1999-08-06

1997-08-27 Priority claimed from US08/920,319 external-priority patent/US6008234A/en

1997-09-11 Application filed by Schering Ag filed Critical Schering Ag

1999-08-06 Publication of SK29599A3 publication Critical patent/SK29599A3/sk

Links

-1 cyclic amino acid Chemical class 0.000 title claims abstract description 554
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical group NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 title claims abstract description 284
239000003146 anticoagulant agent Substances 0.000 title abstract description 7
229940127219 anticoagulant drug Drugs 0.000 title abstract description 7
150000001875 compounds Chemical class 0.000 claims abstract description 246
238000000034 method Methods 0.000 claims abstract description 27
201000010099 disease Diseases 0.000 claims abstract description 21
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
230000001732 thrombotic effect Effects 0.000 claims abstract description 10
125000000217 alkyl group Chemical group 0.000 claims description 238
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 236
125000003118 aryl group Chemical group 0.000 claims description 135
229910052736 halogen Inorganic materials 0.000 claims description 111
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 109
125000003545 alkoxy group Chemical group 0.000 claims description 101
125000003710 aryl alkyl group Chemical group 0.000 claims description 100
125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 92
125000004663 dialkyl amino group Chemical group 0.000 claims description 77
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 75
125000005843 halogen group Chemical group 0.000 claims description 73
150000002367 halogens Chemical class 0.000 claims description 73
125000004356 hydroxy functional group Chemical group O* 0.000 claims description 63
125000004473 dialkylaminocarbonyl group Chemical group 0.000 claims description 50
125000004432 carbon atom Chemical group C* 0.000 claims description 46
150000003839 salts Chemical class 0.000 claims description 45
125000001188 haloalkyl group Chemical group 0.000 claims description 44
IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 42
229910052757 nitrogen Inorganic materials 0.000 claims description 41
239000001257 hydrogen Substances 0.000 claims description 39
229910052739 hydrogen Inorganic materials 0.000 claims description 39
125000000623 heterocyclic group Chemical group 0.000 claims description 38
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 34
125000002950 monocyclic group Chemical group 0.000 claims description 31
125000002619 bicyclic group Chemical group 0.000 claims description 30
229920006395 saturated elastomer Polymers 0.000 claims description 30
125000004104 aryloxy group Chemical group 0.000 claims description 29
125000004438 haloalkoxy group Chemical group 0.000 claims description 29
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
125000004434 sulfur atom Chemical group 0.000 claims description 25
125000004433 nitrogen atom Chemical group N* 0.000 claims description 23
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
229910052799 carbon Inorganic materials 0.000 claims description 20
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 19
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 18
125000005842 heteroatom Chemical group 0.000 claims description 18
229910052760 oxygen Inorganic materials 0.000 claims description 18
239000001301 oxygen Chemical group 0.000 claims description 18
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 15
125000003386 piperidinyl group Chemical group 0.000 claims description 13
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 9
125000001624 naphthyl group Chemical group 0.000 claims description 9
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
229910052717 sulfur Inorganic materials 0.000 claims description 9
239000011593 sulfur Substances 0.000 claims description 9
ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 8
238000011282 treatment Methods 0.000 claims description 8
150000007945 N-acyl ureas Chemical group 0.000 claims description 7
150000001412 amines Chemical group 0.000 claims description 7
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 7
229910052731 fluorine Inorganic materials 0.000 claims description 7
125000004283 imidazolin-2-yl group Chemical group [H]N1C(*)=NC([H])([H])C1([H])[H] 0.000 claims description 7
JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 claims description 7
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 7
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
125000001153 fluoro group Chemical group F* 0.000 claims description 6
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 5
125000002947 alkylene group Chemical group 0.000 claims description 5
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
125000004193 piperazinyl group Chemical group 0.000 claims description 5
125000001116 prolino group Chemical group [H]OC(=O)C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 5
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 3
125000005045 dihydroisoquinolinyl group Chemical group C1(NC=CC2=CC=CC=C12)* 0.000 claims description 3
125000000168 pyrrolyl group Chemical group 0.000 claims description 3
125000001984 thiazolidinyl group Chemical group 0.000 claims description 3
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 2
239000011737 fluorine Substances 0.000 claims description 2
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims description 2
QOTCKDIPQPXNQE-UHFFFAOYSA-N CN1C(=NCC1)C=1C=C(OC2=NC=C(C=C2F)F)C=CC1 Chemical compound CN1C(=NCC1)C=1C=C(OC2=NC=C(C=C2F)F)C=CC1 QOTCKDIPQPXNQE-UHFFFAOYSA-N 0.000 claims 1
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 222
125000002887 hydroxy group Chemical group [H]O* 0.000 description 50
238000012360 testing method Methods 0.000 description 37
108010074860 Factor Xa Proteins 0.000 description 35
239000000243 solution Substances 0.000 description 31
108090000190 Thrombin Proteins 0.000 description 25
229960004072 thrombin Drugs 0.000 description 25
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
238000002360 preparation method Methods 0.000 description 24
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
108010000499 Thromboplastin Proteins 0.000 description 20
102000002262 Thromboplastin Human genes 0.000 description 20
238000006243 chemical reaction Methods 0.000 description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
239000011550 stock solution Substances 0.000 description 19
238000003556 assay Methods 0.000 description 18
239000012131 assay buffer Substances 0.000 description 18
239000011541 reaction mixture Substances 0.000 description 18
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 15
239000004615 ingredient Substances 0.000 description 14
239000012224 working solution Substances 0.000 description 14
239000003112 inhibitor Substances 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
102000004190 Enzymes Human genes 0.000 description 12
108090000790 Enzymes Proteins 0.000 description 12
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
229940088598 enzyme Drugs 0.000 description 12
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
239000002253 acid Substances 0.000 description 11
230000015271 coagulation Effects 0.000 description 11
238000005345 coagulation Methods 0.000 description 11
125000000842 isoxazolyl group Chemical group 0.000 description 11
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
230000000694 effects Effects 0.000 description 10
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 10
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
150000003254 radicals Chemical class 0.000 description 9
125000003107 substituted aryl group Chemical group 0.000 description 9
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
208000007536 Thrombosis Diseases 0.000 description 8
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 8
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 8
230000002401 inhibitory effect Effects 0.000 description 8
230000008569 process Effects 0.000 description 8
229960000187 tissue plasminogen activator Drugs 0.000 description 8
125000004122 cyclic group Chemical group 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
239000000047 product Substances 0.000 description 7
239000002904 solvent Substances 0.000 description 7
239000000758 substrate Substances 0.000 description 7
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 6
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
108010094028 Prothrombin Proteins 0.000 description 6
239000002585 base Substances 0.000 description 6
239000000872 buffer Substances 0.000 description 6
239000002775 capsule Substances 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000000126 substance Substances 0.000 description 6
108010074105 Factor Va Proteins 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
102100027378 Prothrombin Human genes 0.000 description 5
238000003818 flash chromatography Methods 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
239000008101 lactose Substances 0.000 description 5
235000019359 magnesium stearate Nutrition 0.000 description 5
230000037361 pathway Effects 0.000 description 5
229940039716 prothrombin Drugs 0.000 description 5
239000007787 solid Substances 0.000 description 5
PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 4
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
108010054964 H-hexahydrotyrosyl-alanyl-arginine-4-nitroanilide Proteins 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
102100030951 Tissue factor pathway inhibitor Human genes 0.000 description 4
230000009471 action Effects 0.000 description 4
239000000010 aprotic solvent Substances 0.000 description 4
230000037396 body weight Effects 0.000 description 4
239000012267 brine Substances 0.000 description 4
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
229910000024 caesium carbonate Inorganic materials 0.000 description 4
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
239000000284 extract Substances 0.000 description 4
238000000605 extraction Methods 0.000 description 4
239000007789 gas Substances 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 description 4
230000004048 modification Effects 0.000 description 4
238000012986 modification Methods 0.000 description 4
229940068918 polyethylene glycol 400 Drugs 0.000 description 4
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 4
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
229940068968 polysorbate 80 Drugs 0.000 description 4
229920000053 polysorbate 80 Polymers 0.000 description 4
238000011321 prophylaxis Methods 0.000 description 4
229960004063 propylene glycol Drugs 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
238000001356 surgical procedure Methods 0.000 description 4
239000003826 tablet Substances 0.000 description 4
210000003462 vein Anatomy 0.000 description 4
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
206010051055 Deep vein thrombosis Diseases 0.000 description 3
102000009123 Fibrin Human genes 0.000 description 3
108010073385 Fibrin Proteins 0.000 description 3
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 3
108010049003 Fibrinogen Proteins 0.000 description 3
102000008946 Fibrinogen Human genes 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
206010047249 Venous thrombosis Diseases 0.000 description 3
230000003187 abdominal effect Effects 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
238000004166 bioassay Methods 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
235000019994 cava Nutrition 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000001913 cellulose Substances 0.000 description 3
229920002678 cellulose Polymers 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
229950003499 fibrin Drugs 0.000 description 3
229940012952 fibrinogen Drugs 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001802 infusion Methods 0.000 description 3
239000007788 liquid Substances 0.000 description 3
150000007530 organic bases Chemical class 0.000 description 3
108010014806 prothrombinase complex Proteins 0.000 description 3
230000007017 scission Effects 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000013589 supplement Substances 0.000 description 3
239000000829 suppository Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
102000004411 Antithrombin III Human genes 0.000 description 2
108090000935 Antithrombin III Proteins 0.000 description 2
206010053567 Coagulopathies Diseases 0.000 description 2
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
108010054265 Factor VIIa Proteins 0.000 description 2
229940123583 Factor Xa inhibitor Drugs 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
108090000481 Heparin Cofactor II Proteins 0.000 description 2
102100030500 Heparin cofactor 2 Human genes 0.000 description 2
101000651439 Homo sapiens Prothrombin Proteins 0.000 description 2
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
239000005642 Oleic acid Substances 0.000 description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
101800004937 Protein C Proteins 0.000 description 2
102000017975 Protein C Human genes 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
101800001700 Saposin-D Proteins 0.000 description 2
102000012479 Serine Proteases Human genes 0.000 description 2
108010022999 Serine Proteases Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
102000012607 Thrombomodulin Human genes 0.000 description 2
108010079274 Thrombomodulin Proteins 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
230000004913 activation Effects 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
238000005804 alkylation reaction Methods 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
229960005348 antithrombin iii Drugs 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
229960001948 caffeine Drugs 0.000 description 2
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 2
159000000007 calcium salts Chemical class 0.000 description 2
BJDCWCLMFKKGEE-CMDXXVQNSA-N chembl252518 Chemical compound C([C@@](OO1)(C)O2)C[C@H]3[C@H](C)CC[C@@H]4[C@@]31[C@@H]2O[C@H](O)[C@@H]4C BJDCWCLMFKKGEE-CMDXXVQNSA-N 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
229960001231 choline Drugs 0.000 description 2
230000035602 clotting Effects 0.000 description 2
ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000010828 elution Methods 0.000 description 2
150000002148 esters Chemical group 0.000 description 2
ADFASIQRQWKXSJ-UHFFFAOYSA-N ethyl 1-aminocyclopentane-1-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C1(N)CCCC1 ADFASIQRQWKXSJ-UHFFFAOYSA-N 0.000 description 2
229940012414 factor viia Drugs 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229940039715 human prothrombin Drugs 0.000 description 2
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
229910000041 hydrogen chloride Inorganic materials 0.000 description 2
150000001261 hydroxy acids Chemical class 0.000 description 2
125000002883 imidazolyl group Chemical group 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
229910052500 inorganic mineral Inorganic materials 0.000 description 2
238000002955 isolation Methods 0.000 description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
159000000003 magnesium salts Chemical class 0.000 description 2
239000000463 material Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
235000010755 mineral Nutrition 0.000 description 2
239000011707 mineral Substances 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
150000003904 phospholipids Chemical group 0.000 description 2
239000006187 pill Substances 0.000 description 2
239000002798 polar solvent Substances 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229940093429 polyethylene glycol 6000 Drugs 0.000 description 2
229920006316 polyvinylpyrrolidine Polymers 0.000 description 2
159000000001 potassium salts Chemical class 0.000 description 2
239000000843 powder Substances 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
229960000856 protein c Drugs 0.000 description 2
238000011160 research Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000003001 serine protease inhibitor Substances 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
239000012312 sodium hydride Substances 0.000 description 2
229910000104 sodium hydride Inorganic materials 0.000 description 2
159000000000 sodium salts Chemical class 0.000 description 2
239000008259 solid foam Substances 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000002459 sustained effect Effects 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
229960003766 thrombin (human) Drugs 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 2
FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
ICLYJLBTOGPLMC-KVVVOXFISA-N (z)-octadec-9-enoate;tris(2-hydroxyethyl)azanium Chemical compound OCCN(CCO)CCO.CCCCCCCC\C=C/CCCCCCCC(O)=O ICLYJLBTOGPLMC-KVVVOXFISA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
XTGOWLIKIQLYRG-UHFFFAOYSA-N 2,3,4,5,6-pentafluoropyridine Chemical compound FC1=NC(F)=C(F)C(F)=C1F XTGOWLIKIQLYRG-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
229940013085 2-diethylaminoethanol Drugs 0.000 description 1
125000004638 2-oxopiperazinyl group Chemical group O=C1N(CCNC1)* 0.000 description 1
125000004637 2-oxopiperidinyl group Chemical group O=C1N(CCCC1)* 0.000 description 1
OBZBNMGJXZKUJO-UHFFFAOYSA-N 3-(1-methyl-4,5-dihydroimidazol-2-yl)phenol Chemical compound CN1CCN=C1C1=CC=CC(O)=C1 OBZBNMGJXZKUJO-UHFFFAOYSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
WXWYOLTXMVROOJ-UHFFFAOYSA-N 3-hydroxy-4-phenylmethoxybenzonitrile Chemical compound OC1=CC(C#N)=CC=C1OCC1=CC=CC=C1 WXWYOLTXMVROOJ-UHFFFAOYSA-N 0.000 description 1
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
125000005986 4-piperidonyl group Chemical group 0.000 description 1
XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
239000004322 Butylated hydroxytoluene Substances 0.000 description 1
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
108010048049 Factor IXa Proteins 0.000 description 1
108010014172 Factor V Proteins 0.000 description 1
108010054218 Factor VIII Proteins 0.000 description 1
102000001690 Factor VIII Human genes 0.000 description 1
108010074864 Factor XI Proteins 0.000 description 1
108010080805 Factor XIa Proteins 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
229920002683 Glycosaminoglycan Polymers 0.000 description 1
102100030386 Granzyme A Human genes 0.000 description 1
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
101001009599 Homo sapiens Granzyme A Proteins 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 1
108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
235000019502 Orange oil Nutrition 0.000 description 1
239000008118 PEG 6000 Substances 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
206010035226 Plasma cell myeloma Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 1
108010007544 Protease Nexins Proteins 0.000 description 1
102000007324 Protease Nexins Human genes 0.000 description 1
206010037549 Purpura Diseases 0.000 description 1
241001672981 Purpura Species 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010040070 Septic Shock Diseases 0.000 description 1
229940122055 Serine protease inhibitor Drugs 0.000 description 1
101710102218 Serine protease inhibitor Proteins 0.000 description 1
HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
229940122388 Thrombin inhibitor Drugs 0.000 description 1
102000003790 Thrombin receptors Human genes 0.000 description 1
108090000166 Thrombin receptors Proteins 0.000 description 1
208000032109 Transient ischaemic attack Diseases 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000002168 alkylating agent Substances 0.000 description 1
229940100198 alkylating agent Drugs 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
125000000320 amidine group Chemical group 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
230000001455 anti-clotting effect Effects 0.000 description 1
230000002429 anti-coagulating effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
210000001765 aortic valve Anatomy 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
125000002785 azepinyl group Chemical group 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
125000004069 aziridinyl group Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
150000003937 benzamidines Chemical class 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical group C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
229940095259 butylated hydroxytoluene Drugs 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
108090001015 cancer procoagulant Proteins 0.000 description 1
125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
210000001715 carotid artery Anatomy 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000005482 chemotactic factor Substances 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
239000012230 colorless oil Substances 0.000 description 1
239000010949 copper Chemical class 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
238000007887 coronary angioplasty Methods 0.000 description 1
210000004351 coronary vessel Anatomy 0.000 description 1
235000001671 coumarin Nutrition 0.000 description 1
229960000956 coumarin Drugs 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
238000007865 diluting Methods 0.000 description 1
125000004914 dipropylamino group Chemical group C(CC)N(CCC)* 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000001952 enzyme assay Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
JVEQQBIOSGFCPW-UHFFFAOYSA-N ethyl 1-[methyl-(2,3,5,6-tetrafluoropyridin-4-yl)amino]cyclopentane-1-carboxylate Chemical compound FC=1C(F)=NC(F)=C(F)C=1N(C)C1(C(=O)OCC)CCCC1 JVEQQBIOSGFCPW-UHFFFAOYSA-N 0.000 description 1
IVYPBBLVDYMSJI-UHFFFAOYSA-N ethyl 2-[2-(5-cyano-2-phenylmethoxyphenoxy)-3,5,6-trifluoropyridin-4-yl]oxycyclopentane-1-carboxylate Chemical compound CCOC(=O)C1CCCC1OC1=C(F)C(F)=NC(OC=2C(=CC=C(C=2)C#N)OCC=2C=CC=CC=2)=C1F IVYPBBLVDYMSJI-UHFFFAOYSA-N 0.000 description 1
QTRRWFDRILQXER-UHFFFAOYSA-N ethyl 3-[2-(5-cyano-2-phenylmethoxyphenoxy)-3,5,6-trifluoropyridin-4-yl]oxycyclobutane-1-carboxylate Chemical compound C1C(C(=O)OCC)CC1OC1=C(F)C(F)=NC(OC=2C(=CC=C(C=2)C#N)OCC=2C=CC=CC=2)=C1F QTRRWFDRILQXER-UHFFFAOYSA-N 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
229960000301 factor viii Drugs 0.000 description 1
239000003527 fibrinolytic agent Substances 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000006260 foam Substances 0.000 description 1
239000012634 fragment Substances 0.000 description 1
239000012458 free base Substances 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
238000007429 general method Methods 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
150000002357 guanidines Chemical class 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
230000036541 health Effects 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
229920000669 heparin Polymers 0.000 description 1
229960002897 heparin Drugs 0.000 description 1
125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 1
125000002632 imidazolidinyl group Chemical group 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000000937 inactivator Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000001041 indolyl group Chemical group 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000000543 intermediate Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
229910003002 lithium salt Inorganic materials 0.000 description 1
159000000002 lithium salts Chemical class 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
239000011777 magnesium Chemical class 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
NTCZZMMABFORAP-UHFFFAOYSA-N methyl 1-[2-(5-cyano-2-phenylmethoxyphenoxy)-3,5,6-trifluoropyridin-4-yl]oxy-3,4,5-tris(phenylmethoxy)cyclohexane-1-carboxylate Chemical compound C=1C=CC=CC=1COC1C(OCC=2C=CC=CC=2)CC(C(=O)OC)(OC=2C(=C(OC=3C(=CC=C(C=3)C#N)OCC=3C=CC=CC=3)N=C(F)C=2F)F)CC1OCC1=CC=CC=C1 NTCZZMMABFORAP-UHFFFAOYSA-N 0.000 description 1
ITOOJKJFXFQXTM-UHFFFAOYSA-N methyl 1-[2-(5-cyano-2-phenylmethoxyphenoxy)-3,5-difluoro-6-[3-(1-methylimidazol-2-yl)phenoxy]pyridin-4-yl]pyrrolidine-2-carboxylate Chemical compound COC(=O)C1CCCN1C1=C(F)C(OC=2C=C(C=CC=2)C=2N(C=CN=2)C)=NC(OC=2C(=CC=C(C=2)C#N)OCC=2C=CC=CC=2)=C1F ITOOJKJFXFQXTM-UHFFFAOYSA-N 0.000 description 1
JIZBPBMIHKHHDL-UHFFFAOYSA-N methyl 4-[2-(5-cyano-2-phenylmethoxyphenoxy)-3,5,6-trifluoropyridin-4-yl]oxybicyclo[2.2.1]heptane-1-carboxylate Chemical compound C1CC(C(=O)OC)(C2)CCC12OC(C=1F)=C(F)C(F)=NC=1OC1=CC(C#N)=CC=C1OCC1=CC=CC=C1 JIZBPBMIHKHHDL-UHFFFAOYSA-N 0.000 description 1
LUBWUSMZFMBOIQ-UHFFFAOYSA-N methyl 4-hydroxybicyclo[2.2.2]octane-1-carboxylate Chemical compound C1CC2(O)CCC1(C(=O)OC)CC2 LUBWUSMZFMBOIQ-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 description 1
229920003087 methylethyl cellulose Polymers 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
XCVNDBIXFPGMIW-UHFFFAOYSA-N n-ethylpropan-1-amine Chemical group CCCNCC XCVNDBIXFPGMIW-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
230000014508 negative regulation of coagulation Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
125000003518 norbornenyl group Chemical group C12(C=CC(CC1)C2)* 0.000 description 1
125000002868 norbornyl group Chemical group C12(CCC(CC1)C2)* 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
239000010502 orange oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000000399 orthopedic effect Effects 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000005476 oxopyrrolidinyl group Chemical group 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
BSCCSDNZEIHXOK-UHFFFAOYSA-N phenyl carbamate Chemical class NC(=O)OC1=CC=CC=C1 BSCCSDNZEIHXOK-UHFFFAOYSA-N 0.000 description 1
229920002523 polyethylene Glycol 1000 Polymers 0.000 description 1
229940113116 polyethylene glycol 1000 Drugs 0.000 description 1
229940057838 polyethylene glycol 4000 Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
239000000473 propyl gallate Substances 0.000 description 1
235000010388 propyl gallate Nutrition 0.000 description 1
229940075579 propyl gallate Drugs 0.000 description 1
239000011814 protection agent Substances 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000003072 pyrazolidinyl group Chemical group 0.000 description 1
125000003226 pyrazolyl group Chemical group 0.000 description 1
125000002098 pyridazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
210000002796 renal vein Anatomy 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
229940085605 saccharin sodium Drugs 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000036303 septic shock Effects 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
229940035044 sorbitan monolaurate Drugs 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
238000010998 test method Methods 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
229960004559 theobromine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000006090 thiamorpholinyl sulfone group Chemical group 0.000 description 1
125000006089 thiamorpholinyl sulfoxide group Chemical group 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
239000003868 thrombin inhibitor Substances 0.000 description 1
230000000451 tissue damage Effects 0.000 description 1
231100000827 tissue damage Toxicity 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
238000005809 transesterification reaction Methods 0.000 description 1
201000010875 transient cerebral ischemia Diseases 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 1
229940117013 triethanolamine oleate Drugs 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
108010036927 trypsin-like serine protease Proteins 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
239000003039 volatile agent Substances 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000011701 zinc Chemical class 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Animal Behavior & Ethology (AREA)
Hematology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Cosmetics (AREA)
Pyridine Compounds (AREA)

SK295-99A 1996-09-12 1997-09-11 Benzamidine derivatives substituted by cyclic amino acid or cyclic hydroxy acid derivatives and their use as anti-coagulants SK29599A3 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US71306696A	1996-09-12	1996-09-12
US08/920,319 US6008234A (en)	1996-09-12	1997-08-27	Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
PCT/EP1997/004961 WO1998011094A1 (en)	1996-09-12	1997-09-11	Benzamidine derivatives substituted by cyclic amino acid or cycl ic hydroxy acid derivatives and their use as anti-coagulants

Publications (1)

Publication Number	Publication Date
SK29599A3 true SK29599A3 (en)	1999-08-06

Family

ID=27108932

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK295-99A SK29599A3 (en)	1996-09-12	1997-09-11	Benzamidine derivatives substituted by cyclic amino acid or cyclic hydroxy acid derivatives and their use as anti-coagulants

Country Status (18)

Country	Link
US (3)	US6265404B1 (cs)
EP (1)	EP0929547B1 (cs)
JP (1)	JP3565864B2 (cs)
KR (1)	KR20000036017A (cs)
CN (2)	CN1234798A (cs)
AT (1)	ATE228513T1 (cs)
AU (1)	AU723999B2 (cs)
CA (1)	CA2264521A1 (cs)
CZ (1)	CZ86199A3 (cs)
DE (1)	DE69717474T2 (cs)
DK (1)	DK0929547T3 (cs)
ES (1)	ES2188979T3 (cs)
IL (1)	IL128691A (cs)
NO (1)	NO991206L (cs)
NZ (1)	NZ334264A (cs)
PT (1)	PT929547E (cs)
SK (1)	SK29599A3 (cs)
WO (1)	WO1998011094A1 (cs)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK0813525T3 (da)	1995-03-10	2004-02-16	Berlex Lab	Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
US5994375A (en)	1996-02-12	1999-11-30	Berlex Laboratories, Inc.	Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants
US6004985A (en) *	1996-10-09	1999-12-21	Berlex Laboratories, Inc.	Thio acid derived monocylic N-heterocyclics as anticoagulants
AU7976998A (en) *	1997-06-19	1999-01-04	Du Pont Merck Pharmaceutical Company, The	(amidino)6-membered aromatics as factor xa inhibitors
US6686364B2 (en)	1997-12-08	2004-02-03	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
US6140351A (en) *	1997-12-19	2000-10-31	Berlex Laboratories, Inc.	Ortho-anthranilamide derivatives as anti-coagulants
SK9432000A3 (en)	1997-12-19	2001-02-12	Schering Ag	Ortho-anthranilamide derivatives as anti-coagulants, pharmaceutical composition containing such derivatives and use thereof
US6262088B1 (en)	1998-11-19	2001-07-17	Berlex Laboratories, Inc.	Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
US6127376A (en) *	1998-12-04	2000-10-03	Berlex Laboratories, Inc.	Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
MXPA02004218A (es) *	1999-10-28	2002-10-17	Sankyo Co	Derivados de benzamidina.
AU2004203154B2 (en) *	1999-10-28	2006-06-01	Sankyo Company, Limited	Benzamidine derivatives
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
AR040456A1 (es)	2002-06-27	2005-04-06	Bristol Myers Squibb Co	Piridina n-oxidos 2,4 -disubstituidos utiles como inhibidores de transcriptasa inversa del virus de inmunodeficiencia humana
PT1569912E (pt)	2002-12-03	2015-09-15	Pharmacyclics Llc	Derivados 2-(2-hidroxibifenil-3-il)-1h-benzoimidazole-5- carboxamidina como inibidores do fator viia
EA011087B1 (ru)	2002-12-20	2008-12-30	Эмджен Инк.	Соединения и фармацевтические композиции для лечения воспалительных заболеваний
CA2512899A1 (en)	2003-01-14	2004-08-05	Arena Pharmaceuticals Inc.	1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
AR045047A1 (es)	2003-07-11	2005-10-12	Arena Pharm Inc	Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CA2707789A1 (en)	2007-12-19	2009-07-09	Amgen Inc.	Phenyl acetic acid derivatives as inflammation modulators
US8138339B2 (en)	2008-04-16	2012-03-20	Portola Pharmaceuticals, Inc.	Inhibitors of protein kinases
NZ589315A (en)	2008-04-16	2012-11-30	Portola Pharm Inc	2,6-diamino-pyrimidin-5-yl-carboxamides as Spleen tryosine kinase (syk) or Janus kinase (JAK) inhibitors
WO2009143389A1 (en)	2008-05-21	2009-11-26	Ariad Pharmaceuticals, Inc.	Phosphorous derivatives as kinase inhibitors
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
CN103539791B (zh)	2010-09-22	2017-01-11	艾尼纳制药公司	Gpr119 受体调节剂和对与其相关的障碍的治疗
JP5999177B2 (ja)	2011-05-04	2016-09-28	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
MX363551B (es)	2011-11-23	2019-03-27	Portola Pharmaceuticals Inc Star	Compuestos derivados de pirazina como inhibidores de cinasa.
JP6469567B2 (ja)	2012-05-05	2019-02-13	アリアド・ファーマシューティカルズ・インコーポレイテッド	Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
CA3002540C (en)	2015-01-06	2023-11-07	Arena Pharmaceuticals, Inc.	Use of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid for treating conditions related to the s1p1 receptor
WO2016209809A1 (en)	2015-06-22	2016-12-29	Arena Pharmaceuticals, Inc.	Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
ES2987794T3 (es)	2018-06-06	2024-11-18	Arena Pharm Inc	Procedimientos de tratamiento de afecciones relacionadas con el receptor S1P1

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB824908A (en)	1958-06-03	1959-12-09	May & Baker Ltd	Improvements in or relating to triazine derivatives
JPS5922697B2 (ja)	1976-01-13	1984-05-28	エーザイ株式会社	ビス−（メタ−アミジノフエノキシ）−化合物
US5451700A (en)	1991-06-11	1995-09-19	Ciba-Geigy Corporation	Amidino compounds, their manufacture and methods of treatment
EP0518818A3 (en)	1991-06-11	1993-04-28	Ciba-Geigy Ag	Arylethers, their manufacture and use as medicament
ZA928276B (en)	1991-10-31	1993-05-06	Daiichi Seiyaku Co	Aromatic amidine derivates and salts thereof.
WO1993015756A1 (en)	1992-02-14	1993-08-19	Corvas International, Inc.	Inhibitors of thrombosis
DE4213919A1 (de)	1992-04-28	1993-11-04	Thomae Gmbh Dr K	Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
IL106324A (en)	1992-07-17	1998-09-24	Shell Int Research	Transformed pyrimidine compounds, their preparation and use as pesticides
AU675981B2 (en)	1992-12-02	1997-02-27	Bristol-Myers Squibb Company	Guanidinyl-substituted heterocyclic thrombin inhibitors
JPH08504769A (ja)	1992-12-15	1996-05-21	コルバス・インターナショナル、インコーポレイテッド	因子Ｘａの新規インヒビター
US5332822A (en)	1992-12-24	1994-07-26	Bristol-Myers Squibb Company	Heteroaromatic and thioheteroaromatic substituted sulfonamide thrombin inhibitors
WO1994017817A1 (en)	1993-02-12	1994-08-18	Corvas International, Inc.	Inhibitors of thrombosis
US5633381A (en)	1994-07-05	1997-05-27	Berlex Laboratories, Inc.	(Z,Z), (Z,E) and (E,Z) isomers of substituted bis(phenylmethylene)cycloketones
IL115420A0 (en)	1994-09-26	1995-12-31	Zeneca Ltd	Aminoheterocyclic derivatives
DK0813525T3 (da)	1995-03-10	2004-02-16	Berlex Lab	Benzamidinderivater, deres fremstilling og anvendelse som antikoagulanter
US5691364A (en)	1995-03-10	1997-11-25	Berlex Laboratories, Inc.	Benzamidine derivatives and their use as anti-coagulants
US5612363A (en)	1995-06-02	1997-03-18	Berlex Laboratories, Inc.	N,N-di(aryl) cyclic urea derivatives as anti-coagulants
US5849759A (en)	1995-12-08	1998-12-15	Berlex Laboratories, Inc.	Naphthyl-substituted benzimidazole derivatives as anti-coagulants
US5977117A (en) *	1996-01-05	1999-11-02	Texas Biotechnology Corporation	Substituted phenyl compounds and derivatives thereof that modulate the activity of endothelin
US5994375A (en) *	1996-02-12	1999-11-30	Berlex Laboratories, Inc.	Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants
US5753635A (en)	1996-08-16	1998-05-19	Berlex Laboratories, Inc.	Purine derivatives and their use as anti-coagulants
US5693641A (en)	1996-08-16	1997-12-02	Berlex Laboratories Inc.	Bicyclic pyrimidine derivatives and their use as anti-coagulants
US6004985A (en)	1996-10-09	1999-12-21	Berlex Laboratories, Inc.	Thio acid derived monocylic N-heterocyclics as anticoagulants
SK9432000A3 (en)	1997-12-19	2001-02-12	Schering Ag	Ortho-anthranilamide derivatives as anti-coagulants, pharmaceutical composition containing such derivatives and use thereof

1997
- 1997-09-11 CZ CZ99861A patent/CZ86199A3/cs unknown
- 1997-09-11 AU AU43843/97A patent/AU723999B2/en not_active Ceased
- 1997-09-11 AT AT97942015T patent/ATE228513T1/de not_active IP Right Cessation
- 1997-09-11 IL IL128691A patent/IL128691A/en not_active IP Right Cessation
- 1997-09-11 ES ES97942015T patent/ES2188979T3/es not_active Expired - Lifetime
- 1997-09-11 NZ NZ334264A patent/NZ334264A/xx unknown
- 1997-09-11 CA CA002264521A patent/CA2264521A1/en not_active Abandoned
- 1997-09-11 DK DK97942015T patent/DK0929547T3/da active
- 1997-09-11 KR KR1019997001989A patent/KR20000036017A/ko not_active Ceased
- 1997-09-11 WO PCT/EP1997/004961 patent/WO1998011094A1/en not_active Ceased
- 1997-09-11 EP EP97942015A patent/EP0929547B1/en not_active Expired - Lifetime
- 1997-09-11 PT PT97942015T patent/PT929547E/pt unknown
- 1997-09-11 SK SK295-99A patent/SK29599A3/sk unknown
- 1997-09-11 JP JP51325798A patent/JP3565864B2/ja not_active Expired - Fee Related
- 1997-09-11 CN CN97198664A patent/CN1234798A/zh active Pending
- 1997-09-11 DE DE69717474T patent/DE69717474T2/de not_active Expired - Fee Related
1999
- 1999-03-11 NO NO991206A patent/NO991206L/no not_active Application Discontinuation
- 1999-11-12 US US09/438,270 patent/US6265404B1/en not_active Expired - Fee Related
- 1999-11-12 US US09/439,065 patent/US6177473B1/en not_active Expired - Fee Related
- 1999-11-12 US US09/438,354 patent/US6232325B1/en not_active Expired - Fee Related
2001
- 2001-07-03 CN CN01121736A patent/CN1338454A/zh active Pending

Also Published As

Publication number	Publication date
PT929547E (pt)	2003-03-31
CZ86199A3 (cs)	1999-08-11
WO1998011094A1 (en)	1998-03-19
JP2001500147A (ja)	2001-01-09
KR20000036017A (ko)	2000-06-26
NZ334264A (en)	2000-08-25
EP0929547B1 (en)	2002-11-27
NO991206D0 (no)	1999-03-11
DK0929547T3 (da)	2003-03-10
US6265404B1 (en)	2001-07-24
CA2264521A1 (en)	1998-03-19
ES2188979T3 (es)	2003-07-01
DE69717474D1 (de)	2003-01-09
EP0929547A1 (en)	1999-07-21
IL128691A (en)	2007-07-24
CN1338454A (zh)	2002-03-06
AU723999B2 (en)	2000-09-07
NO991206L (no)	1999-05-11
CN1234798A (zh)	1999-11-10
US6232325B1 (en)	2001-05-15
ATE228513T1 (de)	2002-12-15
US6177473B1 (en)	2001-01-23
DE69717474T2 (de)	2003-06-26
JP3565864B2 (ja)	2004-09-15
IL128691A0 (en)	2000-01-31
AU4384397A (en)	1998-04-02

Publication	Publication Date	Title
SK29599A3 (en)	1999-08-06	Benzamidine derivatives substituted by cyclic amino acid or cyclic hydroxy acid derivatives and their use as anti-coagulants
US6008234A (en)	1999-12-28	Benzamidine derivatives substituted by cyclic amino acid and cyclic hydroxy acid derivatives and their use as anti-coagulants
US6221886B1 (en)	2001-04-24	Thio acid derived monocyclic N-heterocyclics as anticoagulants
US6372751B1 (en)	2002-04-16	Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants
US6262088B1 (en)	2001-07-17	Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
US6242454B1 (en)	2001-06-05	Benzamidine derivatives substituted by amino acid and hydroxy acid derivatives and their use as anti-coagulants
SK19399A3 (en)	1999-08-06	Purine derivatives and their use as anti-coagulants
SK19199A3 (en)	1999-07-12	Bicyclic pyrimidine derivatives and their use as anti-coagulants
SK282767B6 (sk)	2002-12-03	Naftyl-substituované benzimidazolové deriváty pôsobiace ako antikoagulačné činidlá, farmaceutický prostriedok obsahujúci tieto látky a použitie týchto látok
MXPA99002396A (en)	2000-06-05	Benzamidine derivatives substituted by cyclic amino acid or cycl ic hydroxy acid derivatives and their use as anti-coagulants